67 related articles for article (PubMed ID: 21070453)
1. Prognostic factors in patients with breast cancer and malignant pleural effusion.
van Galen KP; Visser HP; van der Ploeg T; Smorenburg CH
Breast J; 2010; 16(6):675-7. PubMed ID: 21070453
[No Abstract] [Full Text] [Related]
2. [Differential prognosis of patients with breast cancer with pleuritis carcinomatosa and with pulmonary lymphangiosis carcinomatosa].
Baur M; Schlappack O; Jakesz R; Dittrich C
Wien Klin Wochenschr; 1992; 104(23):714-6. PubMed ID: 1475980
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of 5-year survival among breast cancer patients with malignant pleural effusion receiving intrapleural OK-432 followed by adoptive transfer with cultured effusion lymphocytes].
Kan N
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1559-61. PubMed ID: 14619463
[TBL] [Abstract][Full Text] [Related]
5. [Thoracoscopic video-assisted talcum pleurodesis (TTP)--effective treatment of malignant pleural effusion].
Brünagel G; Decker P; Manekeller S; Hirner A
Zentralbl Chir; 2002 May; 127(5):453-5. PubMed ID: 12058308
[TBL] [Abstract][Full Text] [Related]
6. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma.
Tanrikulu AC; Abakay A; Kaplan MA; Küçüköner M; Palanci Y; Evliyaoglu O; Sezgi C; Sen H; Carkanat Aİ; Kirbas G
Respiration; 2010; 80(6):480-7. PubMed ID: 20881372
[TBL] [Abstract][Full Text] [Related]
7. [Treatment strategies in malignant pleural effusion of breast carcinoma].
Wolters U; Türler A
Zentralbl Chir; 1998; 123 Suppl 5():128-9. PubMed ID: 10063596
[TBL] [Abstract][Full Text] [Related]
8. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
9. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
[TBL] [Abstract][Full Text] [Related]
10. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
11. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
Aryandono T; Harijadi ; Ghozali A
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
[TBL] [Abstract][Full Text] [Related]
12. Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients.
Aoe K; Hiraki A; Yamazaki K; Nakamura Y; Murakami T; Maeda T; Nishimura M; Sugi K; Ueoka H
Int J Oncol; 2006 Jul; 29(1):65-72. PubMed ID: 16773186
[TBL] [Abstract][Full Text] [Related]
13. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up.
Mansour OA; Zekri AR; Harvey J; Teramoto Y; el-Ahmady O
Anticancer Res; 1997; 17(4B):3101-6. PubMed ID: 9329611
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological factors influencing the survival of breast cancer patients with malignant pleural effusion.
Santos GT; Prolla JC; Camillo ND; Zavalhia LS; Ranzi AD; Bica CG
J Bras Pneumol; 2012; 38(4):487-93. PubMed ID: 22964933
[TBL] [Abstract][Full Text] [Related]
15. [Intrapleural administration with OK-432 and cultured autologous pleural effusion lymphocytes for breast cancer patients with malignant pleural effusions: analysis of 84 patients over a 14-year period].
Kan N
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1796-800. PubMed ID: 10560397
[TBL] [Abstract][Full Text] [Related]
16. Increased survivin mRNA in malignant pleural effusion is significantly correlated with survival.
Lan CC; Wu YK; Lee CH; Huang YC; Huang CY; Tsai YH; Huang SF; Tsao TC
Jpn J Clin Oncol; 2010 Mar; 40(3):234-40. PubMed ID: 19933689
[TBL] [Abstract][Full Text] [Related]
17. [Local administration of adriamycin (ADM) for malignant pleural effusion and pericardiac effusion in breast cancer].
Saisho S; Saeki T; Takashima S; Aogi K; Ohsumi S
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2063-8. PubMed ID: 14712766
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of pleural fluid data in patients with malignant effusion.
Bielsa S; Salud A; Martínez M; Esquerda A; Martín A; Rodríguez-Panadero F; Porcel JM
Eur J Intern Med; 2008 Jul; 19(5):334-9. PubMed ID: 18549935
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics and prognosis of triple-negative breast cancer: a report of 305 cases].
Yuan ZY; Wang SS; Gao Y; Su ZY; Luo WB; Guan ZZ
Ai Zheng; 2008 Jun; 27(6):561-5. PubMed ID: 18570725
[TBL] [Abstract][Full Text] [Related]
20. Pleural effusion as a significant prognostic factor in non-small cell lung cancer.
Naito T; Satoh H; Ishikawa H; Yamashita YT; Kamma H; Takahashi H; Ohtsuka M; Hasegawa S
Anticancer Res; 1997; 17(6D):4743-6. PubMed ID: 9494600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
